Your session is about to expire
← Back to Search
Nucleoside Analogue
Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects
Phase 1
Waitlist Available
Research Sponsored by Antios Therapeutics, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new drug called ATI-2173 in healthy Japanese, Chinese, and Non-Asian people. The researchers want to see how the drug moves through the body, if it is safe, and if people can take it without significant side effects. They are also checking if food affects how the drug works in Non-Asian participants.
Eligible Conditions
- Hepatitis B
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: ATI-2173 50 mg Non-AsianExperimental Treatment1 Intervention
Healthy adult non-Asian subjects will receive 50 mg of ATI-2173
Group II: ATI-2173 50 mg JapaneseExperimental Treatment1 Intervention
Healthy adult Japanese subjects will receive 50 mg of ATI-2173
Group III: ATI-2173 50 mg ChineseExperimental Treatment1 Intervention
Healthy adult Chinese subjects will receive 50 mg of ATI-2173
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ATI-2173 50 mg
2021
Completed Phase 1
~40
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Antios Therapeutics, IncLead Sponsor
5 Previous Clinical Trials
198 Total Patients Enrolled
3 Trials studying Hepatitis B
130 Patients Enrolled for Hepatitis B